Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

The implementation of the bioequivalence certification policy in Chile: An analysis of market authorization data.

Kaplan WA, Cárdenas J, Mansilla C, Tobar T, Wirtz VJ.

PLoS One. 2019 May 29;14(5):e0217334. doi: 10.1371/journal.pone.0217334. eCollection 2019.

2.

The costs of diabetes treatment in low- and middle-income countries: a systematic review.

Moucheraud C, Lenz C, Latkovic M, Wirtz VJ.

BMJ Glob Health. 2019 Feb 27;4(1):e001258. doi: 10.1136/bmjgh-2018-001258. eCollection 2019.

3.

Evaluation of the effects of a generic substitution policy implemented in Chile.

Mansilla C, Cárdenas J, Kaplan WA, Wirtz VJ, Kuhn-Barrientos L, Ortíz de Zárate M, Tobar T, Herrera CA.

BMJ Glob Health. 2019 Mar 4;2(Suppl 3):e000922. doi: 10.1136/bmjgh-2018-000922. eCollection 2017.

4.

A perspective on global access to insulin: a descriptive study of the market, trade flows and prices.

Beran D, Laing RO, Kaplan W, Knox R, Sharma A, Wirtz VJ, Frye J, Ewen M.

Diabet Med. 2019 Jun;36(6):726-733. doi: 10.1111/dme.13947. Epub 2019 Apr 7.

PMID:
30888075
5.

Effect of Novartis Access on availability and price of non-communicable disease medicines in Kenya: a cluster-randomised controlled trial.

Rockers PC, Laing RO, Ashigbie PG, Onyango MA, Mukiira CK, Wirtz VJ.

Lancet Glob Health. 2019 Apr;7(4):e492-e502. doi: 10.1016/S2214-109X(18)30563-1. Epub 2019 Feb 21.

6.

A global accountability mechanism for access to essential medicines.

Simão M, Wirtz VJ, Al-Ansary LA, Hill S, Grove J, Gray AL, Nannei C, Hedman L, Das P, Hogerzeil H.

Lancet. 2018 Dec 8;392(10163):2418-2420. doi: 10.1016/S0140-6736(18)32986-6. No abstract available.

PMID:
30527401
7.

Access to Antihypertensive Medicines at the Household Level: A Study From 8 Counties of Kenya.

Syed N, Rockers PC, Vian T, Onyango M, Laing RO, Wirtz VJ.

Glob Heart. 2018 Dec;13(4):247-253.e5. doi: 10.1016/j.gheart.2018.08.001. Epub 2018 Sep 20.

PMID:
30245176
8.

Perceptions of Kenyan adults on access to medicines for non-communicable diseases: A qualitative study.

Onyango MA, Vian T, Hirsch I, Salvi DD, Laing R, Rockers PC, Ashigbie PG, Wirtz VJ.

PLoS One. 2018 Aug 24;13(8):e0201917. doi: 10.1371/journal.pone.0201917. eCollection 2018.

9.

Commitment to Impact: Strengthening Measurement of Industry-Led Access-to-Medicines Programs.

Rockers PC, Reich MR, Kettler H, Wirtz VJ.

Health Syst Reform. 2018;4(3):188-193. doi: 10.1080/23288604.2018.1483710. Epub 2018 Jul 30.

PMID:
30060703
10.

Comparative analysis of essential medicines for cardiovascular diseases in countries of the WHO Eastern Mediterranean Region.

Mehrtash H, Laing R, Wirtz VJ.

East Mediterr Health J. 2018 Jul 17;24(5):427-434. doi: 10.26719/2018.24.5.427.

11.

Equity in access to non-communicable disease medicines: a cross-sectional study in Kenya.

Rockers PC, Laing RO, Wirtz VJ.

BMJ Glob Health. 2018 Jun 22;3(3):e000828. doi: 10.1136/bmjgh-2018-000828. eCollection 2018. Erratum in: BMJ Glob Health. 2018 Aug 10;3(4):e000828corr1.

12.

Access to medicines for asthma, diabetes and hypertension in eight counties of Kenya.

Wirtz VJ, Turpin K, Laing RO, Mukiira CK, Rockers PC.

Trop Med Int Health. 2018 Aug;23(8):879-885. doi: 10.1111/tmi.13081. Epub 2018 Jun 14.

PMID:
29808960
13.

Monetary and nonmonetary household consumption of health services and the role of insurance benefits: An analysis of the Mexico's National Household Income and Expenditure Survey.

Serván-Mori E, Wirtz VJ.

Int J Health Plann Manage. 2018 Oct;33(4):847-859. doi: 10.1002/hpm.2536. Epub 2018 May 23.

PMID:
29790595
14.

Access to asthma medicines at the household level in eight counties of Kenya.

Barakat D, Rockers PC, Vian T, Onyango MA, Laing RO, Wirtz VJ.

Int J Tuberc Lung Dis. 2018 May 1;22(5):585-590. doi: 10.5588/ijtld.17.0664.

PMID:
29663966
15.

The prevalence and correlates of severe depression in a cohort of Mexican teachers.

Soria-Saucedo R, Lopez-Ridaura R, Lajous M, Wirtz VJ.

J Affect Disord. 2018 Jul;234:109-116. doi: 10.1016/j.jad.2018.02.036. Epub 2018 Feb 28.

PMID:
29525351
16.

Beyond availability and affordability: how access to medicines affects non-communicable disease outcomes.

Wirtz VJ, Moucheraud C.

Lancet Public Health. 2017 Sep;2(9):e390-e391. doi: 10.1016/S2468-2667(17)30168-8. Epub 2017 Sep 5. No abstract available.

17.

Comparison of medicines management strategies in insurance schemes in middle-income countries: four case studies.

Kaplan WA, Ashigbie PG, Brooks MI, Wirtz VJ.

J Pharm Policy Pract. 2017 May 16;10:17. doi: 10.1186/s40545-017-0105-y. eCollection 2017.

18.

Essential medicines for universal health coverage - Authors' reply.

Wirtz VJ, Hogerzeil HV, Gray AL; Lancet Commission on Essential Medicines Policies.

Lancet. 2017 May 13;389(10082):1881-1882. doi: 10.1016/S0140-6736(17)31209-6. Epub 2017 May 11. No abstract available.

PMID:
28513447
19.

Industry-Led Access-To-Medicines Initiatives In Low- And Middle-Income Countries: Strategies And Evidence.

Rockers PC, Wirtz VJ, Umeh CA, Swamy PM, Laing RO.

Health Aff (Millwood). 2017 Apr 1;36(4):706-713. doi: 10.1377/hlthaff.2016.1213.

PMID:
28373337
20.

Health facility and skilled birth deliveries among poor women with Jamkesmas health insurance in Indonesia: a mixed-methods study.

Brooks MI, Thabrany H, Fox MP, Wirtz VJ, Feeley FG, Sabin LL.

BMC Health Serv Res. 2017 Feb 2;17(1):105. doi: 10.1186/s12913-017-2028-3.

21.

How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.

Vogler S, Paris V, Ferrario A, Wirtz VJ, de Joncheere K, Schneider P, Pedersen HB, Dedet G, Babar ZU.

Appl Health Econ Health Policy. 2017 Jun;15(3):307-321. doi: 10.1007/s40258-016-0300-z. Review.

PMID:
28063134
22.

Study protocol for a cluster-randomised controlled trial of an NCD access to medicines initiative: evaluation of Novartis Access in Kenya.

Rockers PC, Wirtz VJ, Vian T, Onyango MA, Ashigbie PG, Laing R.

BMJ Open. 2016 Nov 25;6(11):e013386. doi: 10.1136/bmjopen-2016-013386.

23.

Essential medicines for universal health coverage.

Wirtz VJ, Hogerzeil HV, Gray AL, Bigdeli M, de Joncheere CP, Ewen MA, Gyansa-Lutterodt M, Jing S, Luiza VL, Mbindyo RM, Möller H, Moucheraud C, Pécoul B, Rägo L, Rashidian A, Ross-Degnan D, Stephens PN, Teerawattananon Y, 't Hoen EF, Wagner AK, Yadav P, Reich MR.

Lancet. 2017 Jan 28;389(10067):403-476. doi: 10.1016/S0140-6736(16)31599-9. Epub 2016 Nov 8. Review. No abstract available.

PMID:
27832874
24.

Estimating the Burden of Chagas Disease in the United States.

Manne-Goehler J, Umeh CA, Montgomery SP, Wirtz VJ.

PLoS Negl Trop Dis. 2016 Nov 7;10(11):e0005033. doi: 10.1371/journal.pntd.0005033. eCollection 2016 Nov.

25.

Response by Wirtz et al to Letter Regarding Article, "Access to Medications for Cardiovascular Diseases in Low- and Middle-Income Countries".

Wirtz VJ, Kaplan WA, Kwan GF, Laing RO.

Circulation. 2016 Oct 4;134(14):e305-e306. No abstract available.

PMID:
27698055
26.

International short-term medical missions: a systematic review of recommended practices.

Roche SD, Ketheeswaran P, Wirtz VJ.

Int J Public Health. 2017 Jan;62(1):31-42. doi: 10.1007/s00038-016-0889-6. Epub 2016 Sep 3. Review.

PMID:
27592359
27.

Effects of over-the-counter sales restriction of antibiotics on substitution with medicines for symptoms relief of cold in Mexico and Brazil: time series analysis.

Santa-Ana-Tellez Y, Mantel-Teeuwisse AK, Leufkens HG, Wirtz VJ.

Health Policy Plan. 2016 Nov;31(9):1291-6. doi: 10.1093/heapol/czw066. Epub 2016 May 26.

PMID:
27229872
28.

Access to Medications for Cardiovascular Diseases in Low- and Middle-Income Countries.

Wirtz VJ, Kaplan WA, Kwan GF, Laing RO.

Circulation. 2016 May 24;133(21):2076-85. doi: 10.1161/CIRCULATIONAHA.115.008722. Review.

29.

Pharmaceutical policies in a crisis? Challenges and solutions identified at the PPRI Conference.

Vogler S, Zimmermann N, Ferrario A, Wirtz VJ, de Joncheere K, Pedersen HB, Dedet G, Paris V, Mantel-Teeuwisse AK, Babar ZU; Scientific Programme Committee of the 2015 PPRI Conference.

J Pharm Policy Pract. 2016 Mar 15;9:9. doi: 10.1186/s40545-016-0056-8. eCollection 2016.

30.

Challenges of medicines management in the public and private sector under Ghana's National Health Insurance Scheme - A qualitative study.

Ashigbie PG, Azameti D, Wirtz VJ.

J Pharm Policy Pract. 2016 Feb 24;9:6. doi: 10.1186/s40545-016-0055-9. eCollection 2016.

31.

Evaluating the quality and use of economic data in decisions about essential medicines.

Moucheraud C, Wirtz VJ, Reich MR.

Bull World Health Organ. 2015 Oct 1;93(10):693-699. Epub 2015 Aug 14.

32.

Essential medicines are still essential.

Gray AL, Wirtz VJ, 't Hoen EF, Reich MR, Hogerzeil HV.

Lancet. 2015 Oct 24;386(10004):1601-3. doi: 10.1016/S0140-6736(15)00514-0. No abstract available.

PMID:
26595616
33.

Access to Medicines by Seguro Popular Beneficiaries: Pending Tasks towards Universal Health Coverage.

Servan-Mori E, Heredia-Pi I, Montañez-Hernandez J, Avila-Burgos L, Wirtz VJ.

PLoS One. 2015 Sep 25;10(9):e0136823. doi: 10.1371/journal.pone.0136823. eCollection 2015.

34.

[Clinics adjacent to private pharmacies in Mexico: infrastructure and characteristics of the physicians and their remuneration].

Díaz-Portillo SP, Idrovo ÁJ, Dreser A, Bonilla FR, Matías-Juan B, Wirtz VJ.

Salud Publica Mex. 2015 Jul-Aug;57(4):320-8. Spanish.

PMID:
26395797
35.

Reply to "decrease in penicillin sales in Brazil after over-the-counter restrictions".

Santa-Ana-Tellez Y, Mantel-Teeuwisse AK, Leufkens HG, Wirtz VJ.

Antimicrob Agents Chemother. 2015 Sep;59(9):5864. doi: 10.1128/AAC.01128-15. No abstract available.

36.

Access to care for Chagas disease in the United States: a health systems analysis.

Manne-Goehler J, Reich MR, Wirtz VJ.

Am J Trop Med Hyg. 2015 Jul;93(1):108-13. doi: 10.4269/ajtmh.14-0826. Epub 2015 May 18.

37.

Seasonal variation in penicillin use in Mexico and Brazil: analysis of the impact of over-the-counter restrictions.

Santa-Ana-Tellez Y, Mantel-Teeuwisse AK, Leufkens HG, Wirtz VJ.

Antimicrob Agents Chemother. 2015 Jan;59(1):105-10. doi: 10.1128/AAC.03629-14. Epub 2014 Oct 13.

38.

Short report: Increasing access to treatment for Chagas disease: the case of Morelos, Mexico.

Manne-Goehler J, Ramsey JM, Salgado MO, Wirtz VJ, Reich MR.

Am J Trop Med Hyg. 2014 Dec;91(6):1125-7. doi: 10.4269/ajtmh.14-0357. Epub 2014 Sep 29.

39.

Obstetric care and method of delivery in Mexico: results from the 2012 National Health and Nutrition Survey.

Heredia-Pi I, Servan-Mori EE, Wirtz VJ, Avila-Burgos L, Lozano R.

PLoS One. 2014 Aug 7;9(8):e104166. doi: 10.1371/journal.pone.0104166. eCollection 2014.

40.

Effects of the expansion of doctors' offices adjacent to private pharmacies in Mexico: secondary data analysis of a national survey.

Pérez-Cuevas R, Doubova SV, Wirtz VJ, Servan-Mori E, Dreser A, Hernández-Ávila M.

BMJ Open. 2014 May 22;4(5):e004669. doi: 10.1136/bmjopen-2013-004669.

41.

A research agenda to promote affordable and quality assured medicines.

Kaplan WA, Wirtz VJ.

J Pharm Policy Pract. 2014 Mar 13;7:2. doi: 10.1186/2052-3211-7-2. eCollection 2014.

42.

Operational rules for the implementation of INN prescribing.

Van Bever E, Wirtz VJ, Azermai M, De Loof G, Christiaens T, Nicolas L, Van Bortel L, Vander Stichele R.

Int J Med Inform. 2014 Jan;83(1):47-56. doi: 10.1016/j.ijmedinf.2013.09.004. Epub 2013 Oct 5.

PMID:
24168761
43.

Impact of over-the-counter restrictions on antibiotic consumption in Brazil and Mexico.

Santa-Ana-Tellez Y, Mantel-Teeuwisse AK, Dreser A, Leufkens HG, Wirtz VJ.

PLoS One. 2013 Oct 16;8(10):e75550. doi: 10.1371/journal.pone.0075550. eCollection 2013.

44.

The market dynamics of generic medicines in the private sector of 19 low and middle income countries between 2001 and 2011: a descriptive time series analysis.

Kaplan WA, Wirtz VJ, Stephens P.

PLoS One. 2013 Sep 30;8(9):e74399. doi: 10.1371/journal.pone.0074399. eCollection 2013.

45.

[Challenges and opportunities for the development of a national pharmaceutical policy in México].

Wirtz VJ, Dreser A, Heredia-Pi I.

Salud Publica Mex. 2013 May-Jun;55(3):329-36. Spanish.

PMID:
23912546
46.

Measuring universities' commitments to global health.

Wirtz VJ, Vian T, Kaplan WA, Simon JL.

Lancet. 2013 Jul 20;382(9888):204-5. doi: 10.1016/S0140-6736(13)61595-0. No abstract available.

PMID:
23870527
47.

Financing HIV programming: how much should low- and middle-income countries and their donors pay?

Galárraga O, Wirtz VJ, Santa-Ana-Tellez Y, Korenromp EL.

PLoS One. 2013 Jul 5;8(7):e67565. doi: 10.1371/journal.pone.0067565. Print 2013.

48.

Analysing policy interventions to prohibit over-the-counter antibiotic sales in four Latin American countries.

Wirtz VJ, Herrera-Patino JJ, Santa-Ana-Tellez Y, Dreser A, Elseviers M, Vander Stichele RH.

Trop Med Int Health. 2013 Jun;18(6):665-73. doi: 10.1111/tmi.12096. Epub 2013 Mar 29. Review.

49.

Promotion of access to essential medicines for non-communicable diseases: practical implications of the UN political declaration.

Hogerzeil HV, Liberman J, Wirtz VJ, Kishore SP, Selvaraj S, Kiddell-Monroe R, Mwangi-Powell FN, von Schoen-Angerer T; Lancet NCD Action Group.

Lancet. 2013 Feb 23;381(9867):680-9. doi: 10.1016/S0140-6736(12)62128-X. Epub 2013 Feb 12. Review.

PMID:
23410612
50.

Use of antibacterial fixed-dose combinations in the private sector in eight Latin American Countries between 1999 and 2009.

Wirtz VJ, Mol PG, Verdijk J, Vander Stichele RH, Taxis K.

Trop Med Int Health. 2013 Apr;18(4):416-25. doi: 10.1111/tmi.12068. Epub 2013 Feb 5.

Supplemental Content

Loading ...
Support Center